Evidence map›Paper›PMID 34556744›Full record

ArticleScientific reports2021

Quantitative assessment of sensitizing potency using a dose-response adaptation of GARDskin.

Robin Gradin, Andy Forreryd, Ulrika Mattson, Anders Jerre, Henrik Johansson

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Robin GradinSenzaGen AB, Medicon Village, Scheelevägen 2, 22381, Lund, Sweden.
Andy ForrerydSenzaGen AB, Medicon Village, Scheelevägen 2, 22381, Lund, Sweden.
Ulrika MattsonSenzaGen AB, Medicon Village, Scheelevägen 2, 22381, Lund, Sweden.
Anders JerreSenzaGen AB, Medicon Village, Scheelevägen 2, 22381, Lund, Sweden.
Henrik JohanssonSenzaGen AB, Medicon Village, Scheelevägen 2, 22381, Lund, Sweden. henrik.johansson@senzagen.com.
Medicon Village · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hundreds of chemicals have been identified as skin sensitizers. These are chemicals that possess the ability to induce hypersensitivity reactions in humans, giving rise to a condition termed allergic contact dermatitis. The capacity to limit hazardous exposure to such chemicals depends upon the ability to accurately identify and characterize their skin sensitizing potency. This has traditionally been accomplished using animal models, but their widespread use offers challenges from both an ethical and a scientific perspective. Comprehensive efforts have been made by the scientific community to develop new approach methodologies (NAMs) capable of replacing in vivo assays, which have successfully yielded several methods that can identify skin sensitizers. However, there is still a lack of new approaches that can effectively measure skin sensitizing potency. We present a novel methodology for quantitative assessment of skin sensitizing potency, which is founded on the already established protocols of the GARDskin assay. This approach analyses dose-response relationships in the GARDskin assay to identify chemical-specific concentrations that are sufficient to induce a positive response in the assay. We here compare results for 22 skin sensitizers analyzed using this method with both human and LLNA potency reference data and show that the results correlate strongly and significantly with both metrics (r

Indexed as

AllergensAnimal Testing AlternativesBiological AssayCell LineDermatitis, Allergic ContactDose-Response Relationship, ImmunologicHumansLangerhans CellsSkinToxicologyAllergens

Identifiers

PMID34556744
PMCPMC8460622
OpenAlexW3199767964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.